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The contribution of gluconeogenesis to hepatic glucose pro-
duction (GP) was quantified after 2H2O ingestion by Bayesian
analysis of the position 2 and 5 2H-NMR signals (H2 and H5) of
monoacetone glucose (MAG) derived from urinary acetamino-
phen glucuronide. Six controls and 10 kidney transplant (KTx)
patients with cyclosporine A (CsA) immunosuppressant therapy
were studied. Seven KTx patients were lean and euglycemic
(BMI  24.3  1.0 kg/m2; fasting glucose  4.7  0.1 mM) while
three were obese and hyperglycemic (BMI  30.5  0.7 kg/m2;
fasting glucose  7.1  0.5 mM). For the 16 spectra analyzed,
the mean coefficient of variation for the gluconeogenesis con-
tribution was 10%  5%. This uncertainty was associated with
a mean signal-to-noise ratio (SNR) of 79:1 and 45:1 for the MAG
H2 and H5 signals, respectively. For control subjects, glucone-
ogenesis contributed 54%  7% of GP as determined by the
mean and standard deviation (SD) of individual Bayesian anal-
yses. For the lean/normoglycemic KTx subjects, the gluconeo-
genic contribution to GP was 62%  7% (P  0.06 vs. controls),
while hyperglycemic/obese KTx patients had a gluconeogenic
contribution of 68%  3% (P < 0.005 vs. controls). These data
suggest that in KTx patients, an increased gluconeogenic con-
tribution to GP is strongly associated with obesity and
hyperglycemia. Magn Reson Med 60:517–523, 2008. © 2008
Wiley-Liss, Inc.
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Plasma glucose levels are maintained over the daily feed-
ing/fasting cycle through tight coordination of glucose ap-
pearance and disposal. During overnight fasting, glucose
appearance is entirely accounted for by endogenous glu-
cose production (GP) once digestive absorption has
ceased. The occurrence of hyperglycemia after overnight
fasting is a hallmark of defective glucose metabolism and
indicates a mismatch between GP and plasma glucose
clearance. Impaired glucose uptake by peripheral tissues
and inappropriately high levels of hepatic GP can both
contribute to this condition. Among other things, resolving
these underlying defects could prove useful for guiding
and evaluating interventions of fasting hyperglycemia,
since some antihyperglycemic medications act by inhibit-
ing GP while others function by improving whole-body
glucose uptake.
Systemic glucose metabolism is typically assessed in the
clinical setting by quantifying plasma glucose levels before
and after an oral glucose load, but this approach does not
provide any information about hepatic glucose metabo-
lism. Assessment of GP with stable-isotope tracers could
provide useful information to complement measurements
of plasma glucose clearance; however, current methods are
poorly suited for routine clinical studies. This is due to
several factors, including high tracer cost, the requirement
of lengthy infusion times for administration of the tracer,
and extensive sample processing and analysis.
Deuterated water (2H2O) is an inexpensive tracer of glu-
coneogenesis that can be administered orally and is there-
fore well suited for routine clinical study procedures. The
metabolic information is derived from the analysis of the
2H-enrichment distribution of plasma glucose (1–7). Cur-
rent gas chromatography-mass spectrometry (GC-MS)
methods, while highly sensitive and therefore applicable
to small blood samples, are labor-intensive and poorly
suited for high sample throughputs. Analysis by 2H NMR
spectroscopy of the monoacetone glucose (MAG) deriva-
tive of plasma glucose is less sensitive but far simpler to
the extent that both sample preparation and NMR spec-
troscopy can be extensively automated with current tech-
nologies. Conversion of plasma glucose to MAG has been
successfully performed with a commercially available ro-
botic chemical synthesizer (8), and high-resolution 2H
NMR spectra of the product can be obtained with auto-
mated tuning/shimming routines and minimal technical
oversight. The contribution of gluconeogenic and glyco-
genolytic fluxes to GP can be automatically obtained from
the 2H NMR signal by Bayesian/Markov chain Monte Carlo
(MCMC) analysis of the free induction decay (FID) (9). The
analysis also provides estimates of uncertainty levels for
the flux parameters. Data modeling studies indicate that
these uncertainty levels are heavily influenced by the sig-
nal-to-noise ratio (SNR) of the 2H NMR signal. For practical
and safety reasons, human body water 2H-enrichment from
2H2O is limited to 0.3% to 0.5%. To obtain 2H NMR signals
of suitable SNRs for Bayesian analysis requires a large
sample size (30 ml of whole blood) and/or long NMR
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collection times, which limits the practicality and
throughput of the method.
Due to rapid exchange between hepatic glucose-6-phos-
phate (G6P) and glucose-1-phosphate (G1P), the 2H-enrich-
ment distribution of plasma glucose is also reflected in
hydrogens 1–5 of acetaminophen glucuronide (see Fig. 1)
(10). In addition to eliminating the need to collect and
rapidly process blood samples, the quantity of urinary
glucuronide that is available for analysis is typically 5–10
times that of plasma glucose. Under these conditions, we
anticipated that 2H NMR spectra with sufficient SNR to
yield reasonably precise estimates of gluconeogenesis by
Bayesian analysis could be obtained without prohibitively
long NMR collection times. The Bayesian method is ideal
for analyzing data of this type. Experimental time con-
straints prevent repeated measurements upon the same
sample to construct a more traditional statistical estimate
of the uncertainty, i.e., the mean and standard deviation
(SD) of repeated NMR spectra for a given sample. The
Bayesian formulation of this problem uses prior knowl-
edge regarding the shifts and amplitudes of the relevant
resonances, as well as a model for the “nuisance” reso-
nances that are not important for the metabolic measure-
ments. A MCMC simulation makes multiple independent
analyses of the posterior probability distribution that de-
fine the metabolic measurement. This provides an estimate
of the most probable values of the metabolic parameters, as
well as the uncertainty value for each parameter.
In this study the gluconeogenic contribution to GP after
overnight fast was estimated by Bayesian analyses of the
2H NMR signals of urinary acetaminophen glucuronide
collected after overnight ingestion of 2H2O and acetamin-
ophen followed by derivatization to MAG. The analysis
was applied to healthy subjects and kidney transplant
(KTx) recipients, including a subgroup diagnosed with
posttransplant diabetes. The development of hyperglyce-
mia and posttransplant diabetes is a frequent event follow-
ing kidney transplantation (11,12). This may involve sev-
eral factors, including increased adiposity, and glucose
intolerance resulting from posttransplant weight gain, age,
and ethnicity (11), as well as the direct action of immuno-
suppressive agents such as glucocorticoids and the cal-
cineurin inhibitor, cyclosporine A (CsA), on insulin secre-
tion and sensitivity (13,14). The activity of hepatic glu-
coneogenesis and its contribution to posttransplant
hyperglycemia under these conditions is not known. In
this study, sources of fasting GP derived by Bayesian anal-
ysis were collated with plasma metabolite and insulin
sensitivity measurements.
MATERIALS AND METHODS
Human Studies
The study protocol was approved by the University Hos-
pital of Coimbra Ethics Committee and was performed in
accordance with the ethical standards laid down in the
Helsinki Declaration. Subjects were studied in the Depart-
ment of Endocrinology, Metabolism and Diabetes in the
University Hospital of Coimbra after they provided in-
formed consent. Three groups were studied as follows:
Group I: six healthy, lean normoglycemic controls; Group
II: seven lean, normoglycemic patients with a functional
KTx with stable ongoing CsA-based therapy; and Group III:
three obese and hyperglycemic patients with a functional
renal transplant and CsA-based therapy. All KTx patients
received 200–400 mg/day of CsA in conjunction with a
low dose of corticoids (5 mg/day).
2H2O Administration and Sampling
Fasting was started at 20:00 (24-h clock) the previous
evening after a normal dinner meal. At 01:00 and 03:00 the
next day, patients were given two loading doses of 2H2O
(2.5 g/kg of body water) to achieve a target body water
enrichment of 0.5% 2H2O. Body water was assumed to be
60% of body weight for males and 50% of body weight for
females. To improve palatability and decrease the risk of
vertigo, each loading was diluted with bottled spring water
to give a final enrichment of 35% 2H2O. Acetaminophen
(1000 mg) was also taken at 03:00. At 06:00 the patients
were asked to empty their bladder and all urine was col-
lected from 06:00 to 08:00. Blood for clinical analysis was
also drawn at 06:00 and 08:00.
Biochemical Analysis
Blood collected at 10 h of fasting was analyzed for plasma
glucose, insulin, C-peptide, cholesterol, high-density li-
poprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol, triglycerides, glycosylated hemoglobin,
creatinine, and ureic nitrogen levels in the laboratories of
University Hospital of Coimbra. Plasma free fatty acid
(FFA) levels were determined independently, using an
enzymatic colorimetric method kit from Wako Chemicals
GmbH, in plasma collected at 12 h of fasting.
Sample Processing
Acetaminophen glucuronide from the 06:00 and 08:00
urine samples was derivatized to MAG as previously de-
scribed (15,16). Briefly, urine was concentrated to 10% of
its original volume and this portion was mixed with 9
volumes of 100% ethanol. The precipitate was centri-
FIG. 1. Metabolic pathways evolved in fasting hepatic glucose me-
tabolism after 2H2O and acetaminophen ingestion. Uridine diphos-
phoglucose (UDPG), glucose-1-phosphate (G1P), glucose-6-phos-
phate (G6P), fructose-1-phosphate (F6P), fructose-1,6-biphosphate
(F1,6P), dihydroxyacetone phosphate (DHAP), phosphoenolpyru-
vate (PEP).
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fuged, the supernatant was evaporated to 10 ml, and the
pH was adjusted to 8.0–9.0 with 1 M NaOH. The super-
natant was applied to an 18  1 cm diameter Dowex-1X8-
200-acetate column. The column was washed with 35 ml
of water, the glucuronide was eluted with 35 ml of 10 M
acetic acid, and the acetic acid fraction was evaporated to
dryness at 40–50°C. The residue was resuspended in 50 ml
water and the pH was adjusted to 4.5–5.0. The acetamin-
ophen glucuronide in this solution was derivatized to
monoacetoneglucuronic lactone (MAGL). A total of 2000
units of -glucuronidase (H. Pomatia; Sigma Chemical
Company) were added and the solution was incubated at
45°C for 48 h. The solution was then passed through 10 ml
Dowex-50X8-200 H ion-exchange resin and evaporated to
complete dryness at 40°C, resulting in the conversion of
free glucuronic acid to glucuronolactone. The lactone was
converted to MAGL by stirring for 24 h with 5 ml of
anhydrous acetone and 0.1 ml concentrated H2SO4. The
yellow solution was mixed with 5 ml water, the pH was
adjusted to between 4 and 5 with 0.5 M Na2CO3, and the
solution was evaporated to dryness at room temperature.
MAGL was extracted from the salt products with 2–3 ml
acetonitrile and reduced to MAG with lithium borohy-
dride using tetrahydrofuran as the solvent (15).
NMR Spectroscopy
2H NMR spectra were acquired at 11.75 T with a Varian
Unity 500 Spectrometer equipped with a 5-mm broadband
“switchable” probe with z-gradient (Varian, Palo Alto, CA,
USA). MAG was dissolved in 90% acetonitrile/10% water,
and shimming was performed on selected 1H resonances of
MAG. Proton-decoupled 2H NMR spectra were acquired
without field-frequency lock at 50°C using a 90° pulse and
a 1.6-s acquisition time. Typically 6000-30,000 FIDs were
collected (2.7–13.5 h total collection time). For the deter-
mination of urine water 2H enrichment using the method
of Jones et al. (17), spectra were obtained at 25°C using a
22.5° pulse and a 4-s acquisition time.
Bayesian/MCMC Analysis of Glucuronide Metabolic
Fluxes
G6P derived from glycogenolysis has deuterium in posi-
tion 2 only, as a result of exchange between G6P and
fructose-6-phosphate (F6P), whereas G6P derived from
any gluconeogenic precursor has deuterium incorporated
in both positions 2 and 5 due to additional exchanges at
the triose phosphate level. Hence, the ratios of 2H enrich-
ment in positions 5 and 2 (H5/H2) of G6P and plasma
glucose reflect the fractional contribution of gluconeogen-
esis to fasting GP. The glucuronide moiety of acetamino-
phen is assumed to be derived from a hepatic uridine
diphosphate (UDP)-glucose pool that is in isotopic steady
state with hepatic G6P as a result of rapid G6P-G1P ex-
change (18). On this basis, glucuronide H5/H2 is identical
to that of hepatic G6P, and the fractional contributions of
glycogenolysis and gluconeogenesis to GP are given by the
following equations:
Gluconeogenesis fraction
 Glucuronide H5/Glucuronide H2 [1]
Glycogenolysis fraction
 1  (Glucuronide H5/Glucuronide H2) [2]
The H5/H2 parameter is thus obtained from the ratio of the
glucuronide 2H NMR signals for these positions. This pa-
rameter can be obtained in an operator-independent man-
ner by Bayesian analysis of the FID, as previously de-
scribed (9). The posterior probability distribution for the
gluconeogenesis and glycogenolysis fractions was ob-
tained from a MCMC simulation consisting of 50 indepen-
dent Markov chains, from each of which 50 independent
samples were drawn (a total of 2500 samples [9]). Esti-
mates of the mean and SD for each flux parameter were
derived from this sample set.
Data Analysis
Statistical differences were determined using one-way
analysis of variance (ANOVA). P  0.05 was considered to
be statistical significant.
RESULTS
Plasma Metabolite and Hormone Levels
Table 1 provides a summary of plasma metabolite and
insulin levels along with body mass index (BMI), age, and
gender for all subjects. There were no significant differ-
ences in the plasma levels of insulin, C-peptide, choles-
terol, HDL cholesterol, LDL cholesterol, triglycerides, and
FFA between healthy controls and either of the KTx pa-
tient groups. All patients treated with CsA showed signif-
icant increases in plasma creatinine and ureic nitrogen
relative to healthy controls. These observations likely re-
flect an impairment in kidney function due to the nephro-
toxic effects of CsA (19). Hyperglycemic patients had sig-
nificantly higher fasting plasma glucose levels on the
morning of the study, as well as higher values of glycosy-
lated hemoglobin. This indicates that the hyperglycemia
in these patients was well established prior to the study.
This group also had a significantly higher BMI and age
average compared to both normoglycemic transplant pa-
tients and the healthy control group.
2H-Enrichment Distribution of Body Water and Urinary
Glucuronide
Steady-state body water enrichments were 0.53% 0.01%
in the hyperglycemic obese KTx patients treated with CsA.
This was significantly higher than that of controls (0.43%
 0.01%, P  0.01) and the normoglycemic KTx patients
treated with CsA (0.48% 0.02%, P 0.05). These results
are consistent with a reduction in body water and an
increased body fat fraction for the hyperglycemic post-
transplant patients.
2H NMR spectra of MAG derived from acetaminophen
glucuronide generated well-resolved 2H MAG resonances,
with SNRs of the hydrogen 5 signal ranging from 20:1 to
60:1. Both the sample mass and the 2H-NMR spectra de-
rived from healthy controls were consistent with those
recently reported in a study of overnight-fasted healthy
controls (16). Enrichment of position 2, reflecting isotope
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equilibration with body water, was estimated to be 86% 
12% that of body water. This indicates that the exchange
between hydrogen 2 of hepatic G6P and that of body water
via interconversion of G6P and F6P was essentially com-
plete. This is in agreement with recent reports in which it
was found that after 5 h of 2H2O incubation, plasma 2H2O
and H2 were equilibrated (16). Other MAG 2H-signals cor-
responding to positions 3, 4, and 5 of glucuronide were
less intense, indicating dilution of 2H-enrichment at these
sites by G6P derived from unlabeled hepatic glycogen. As
was previously observed with glucuronide enrichment
distributions from 2H2O in healthy subjects and in Type 1
diabetic patients, the hydrogen 4 and 5 positions were
enriched to similar levels (10,16). The ratio of hydrogen 3
enrichment relative to hydrogen 2 (H3/H2) was signifi-
cantly lower than that of H5/H2 (0.26  0.02 vs. 0.47 
0.05, P  0.005 for controls; and 0.45  0.04 vs. 0.62 
0.03, P  0.0002 for posttransplant patients). The differ-
ence in enrichment between positions 3 and 5 could be the
result of incomplete exchange of 1R-dihydroxyacetone
phosphate (the precursor of G6P hydrogen 3) with body
water deuterium via triose phosphate isomerase, possibly
due to isotopic discrimination. If so, then hydrogen 3
enrichment would systematically underestimate the glu-
coneogenic contribution to GP. In addition, the difference
in enrichment between hydrogens 3 and 5 could also re-
flect transaldolase activity, which catalyzes the exchange
of the 456 carbon fragment of fructose-6-P with free glyc-
eraldehyde-3-phosphate (20). Since transaldolase ex-
change results in the enrichment of unlabeled F6P (i.e.,
that derived from glycogenolysis) in positions 4, 5, and 6,
this activity would contribute to hydrogen 5 enrichment of
G6P independently of gluconeogenic flux, whereas hydro-
gen 3 enrichment would not be affected.
Gluconeogenesis and Glycogenolysis Contributions to GP
by Bayesian/MCMC Analysis
A summary of the Bayesian/MCMC estimates of the frac-
tional contributions of gluconeogenesis and glycogenoly-
sis to GP for each subject, along with the SNR of the
Fourier-transformed 2H NMR spectrum of MAG, is shown
in Table 2. Generally, the precision of the flux estimates, as
determined by the size of the SDs, was highest for spectra
with high SNRs (i.e., 40–60:1 for the position 5 reso-
nance). The effects of improving the SNR of the 2H NMR
signal on the Bayesian output are illustrated in Fig. 2. The
initial spectrum had SNRs of 40:1 and 21:1 for the hydro-
gen 2 and 5 signals, respectively. The resulting flux esti-
mates had unacceptably high SDs, hence the NMR spec-
trum was reacquired with an increased number of FIDs,
which resulted in an approximately twofold increase of
the SNR. When these data were processed by Bayesian
analysis, the SD range for the flux estimates was reduced
by about one-half, in accord with the one-half reduction in
spectrum SNR. The improved precision was also accom-
panied by a shift to a lower value for the fractional glu-
coneogenesis estimate. These experimental observations
are highly consistent with the predicted effects of noise
levels on the Bayesian output for gluconeogenic flux using
simulated data (9). As noise levels were increased, the SD
for gluconeogenic flux decreased while the estimate frac-
tional gluconeogenic flux was shifted upwards of the the-
oretical value (9).
Our results also indicate that the precision of the Bayes-
ian analysis is related to the relative intensities of the H5
and H2 signals independently of their individual SNRs. As
seen in Table 2, 2H NMR spectra derived from controls and
from hyperglycemic KTx patients had comparable SNRs
for H2 and H5. However, metabolic flux outputs from the
spectra of the KTx patients had smaller SDs compared to
Table 1
Characteristics of the Different Groups Studied†
Group I: Controls
Group II: Normoglycemic
treated with CsA
Group III: Hyperglycemic
treated with CsA
Gender (male/female) 3/3 7/0 3/0
Age (years) 39  6 45  2 58  4*,***
BMI (kg/m2) 26.2  1.6 24.3  1.0 30.5  0.7*,***
Glucose (mM) 4.8  0.2 4.7  0.1 7.1  0.5*,****
Insulin (	UI/ml) 7.3  2.9 10.7  5.8 4.5  0.2
C-peptide (nM) 2.6  0.9 3.0  0.7 2.7  0.3
Cholesterol (mg/dl) 189.8  14.8 217.7  16.9 209.7  18.7
HDL cholesterol (mg/dl) 51.8  3.9 46.1  5.6 65.0  18.8
LDL cholesterol (mg/dl) 119.3  13.3 141.6  12.1 130.7  29.5
Triglycerides (mg/dl) 179.2  80.6 166.0  25.3 171.7  50.5
Glycosylated hemoglobin (%) 5.7  0.2 5.6  0.2 7.2  0.4*
Creatinine (mg/dl) 1.0  0.1 1.3  0.1* 1.2  0.0*
Ureic nitrogen (mg/dl) 14.8  1.5 25.9  2.4** 21.7  3.2*
Plasma free-fatty acids (mmol/liter) 0.31  0.07 0.39  0.05 0.45  0.12
HOMA-IR 1.7  0.7 2.2  1.2 1.4  0.2
†Biochemical parameters corresponding to blood samples collected at 10-h fast and FFA plasma levels at 12-h fast. Results are shown as
mean  SEM.
*P  0.05, relative to controls.
**P  0.01 relative to controls.
***P  0.05, relative to normoglycemic patients treated with cyclosporine.
****P  0.01 relative to normoglycemic patients treated with cyclosporine.
520 Delgado et al.
those of controls (5%  1% vs. 7%  2%). Aside from a
higher H5/H2 intensity ratio (0.64 vs. 0.54), the spectra
derived from the patients were similar to those of the
control group in terms of signal linewidths and resolution.
Our results suggest that when the gluconeogenic contribu-
tion is low (i.e., less than 50% of GP), the SNR of the H5
signal should be at least 60:1 to obtain reasonably low
levels of uncertainty (i.e., a coefficient of variation of 10%
or less). With higher gluconeogenic contributions (
65%
of GP), a similar level of precision can be obtained from
spectra with H5 SNRs of only 30:1.
For the six control subjects, the mean contribution of
gluconeogenesis and glycogenolysis to GP was 54%  7%
and 46%  7%, respectively (Fig. 3). This is in good
agreement with previous estimates of gluconeogenesis de-
rived by the 2H2O method using 2H NMR analysis of
plasma glucose derived to MAG (3,4,10) as well as GC-MS
analysis of plasma glucose (1,2). Our data are also in good
agreement with values obtained by 2H NMR analysis of
MAG derived from urinary glucuronide (10,16).
The gluconeogenic and glycogenolysis contribution to
GP for all the patients on CsA treatment was 64%  7%
Table 2
Estimates of Fractional Gluconeogenesis and Glycogenolysis Contributions to GP as Determined by Bayesian Analysis and
Represented as Mean  SD of the Bayesian Posterior Probabilities (SDBPP) for Each Subject†
Subject
% GP from
gluconeogenesis
% GP from
glycogenolysis
H2 SNR H5 SNR
Group I: controls
AS 56  10 44  10 22.6 11.6
FP 55  8 45  8 66.4 33.1
IL 51  7 49  7 143.4 64.6
RC 43  7 57  7 69.7 35.7
RAC 55  3 45  3 130.9 63.5
TD 64  9 36  9 47.2 28.2
Average  SD 54  7 46  7
Group II: normoglycemic treated with CsA
AB 54  6 46  6 80.2 46.5
AL 55  6 45  6 71.4 30.8
AM 69  5 31  5 80.6 52.8
AR 68  4 32  4 70.0 45.6
FO 70  4 30  4 55.1 44.0
LC 60  5 40  5 158.2 96.4
LS 58  2 42  2 86.2 51.7
Average  SD 62  7 38  7
Group III: hyperglycemic treated with CsA
AM 69  5 31  5 30.9 22.2
AC 70  4 30  4 62.6 34.6
FS 65  4 35  4 95.2 59.6
Average  SD 68  3* 32  3*
†Also shown are the signal-to-noise ratios (SNRs) of the deuterium 2 and 5 signals (H2 and H5) of MAG as determined after Fourier
transformation of the free-induction decay and applying of 1-Hz line-broadening using the NUTS NMR processing software.
*P  0.05 relative to controls.
FIG. 2. 2H NMR spectra from a MAG sample prepared from a
healthy control subject (FP) with the accumulation of 34,000 FIDs
(bottom spectrum) and 66,500 FIDs (top spectrum). Also shown are
the estimates for glycogenolysis and gluconeogenesis contribution
to hepatic glucose production (SD of the Bayesian posterior prob-
abilities [SDBPP]) and the SNR of the position 2 (H2) and 5(H5)
signal.
FIG. 3. Percentage of glucose production from gluconeogenesis for
each subject studied represented as the mean SD of the Bayesian
posterior probabilities (SDBPP). The dotted line corresponds to the
average of the gluconeogenic contribution to GP of the subjects in
the control group, and the gray zone to the upper and lower limits of
the respective SD.
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and 33%  7%, respectively (P  0.05, relative to con-
trols). The lean normoglycemic KTx patients had a wider
range of gluconeogenic contributions to GP with a ten-
dency towards a modestly increased gluconeogenic con-
tribution to GP (P  0.06 relative to controls). For the
obese, hyperglycemic posttransplant patients, the glu-
coneogenic contribution to GP approached 70%. This es-
timate is somewhat higher than the value of 64% deter-
mined in healthy obese subjects by the 2H2O method, but
is in excellent agreement with the value of 68% obtained
from obese subjects with T2D (21). There was no signifi-
cant relationship between the fractional contribution of
gluconeogenesis and any of the reported clinical parame-
ters.
DISCUSSION
Our work demonstrates the feasibility and some limita-
tions of quantifying fractional gluconeogenesis from Land-
au’s 2H2O method by Bayesian time-domain analysis of
glucuronide enrichment in positions 5 and 2. As a result of
the relatively large sample mass provided by glucuronide
harvesting, 2H NMR spectra with high SNR were obtained
with a standard 11.75T spectrometer and 5-mm broadband
probe. The accuracy and precision of the Bayesian analysis
is largely dependent on the SNR of the 2H NMR spectrum.
For a given sample, improving the SNR proportionally
reduces the SDs and improves the accuracy of the flux
measurements, in accord with simulated noise data.
Among other things, this is a valuable tool for objectively
determining the relationship between the sample collec-
tion time and statistical power of the analysis.
From the patient’s perspective, urinary glucuronide
analysis is a more convenient and less invasive alternative
to blood sampling. In addition, urinary glucuronide is far
less susceptible than plasma glucose to degradation from
delayed processing or storage above –80°C. In our experi-
ence, plasma glucose storage at –20°C for more than 1
month results in a marked decrease in glucose recovery as
MAG, whereas urinary glucuronide is stable for at least 4
months under these conditions. However, there are several
disadvantages to acetaminophen glucuronide analysis
compared to that of plasma glucose. The derivatization of
acetaminophen glucuronide to MAG involves several ad-
ditional steps compared to that of plasma glucose, and is
therefore far less amenable for routine automation. In prin-
ciple, the Bayesian analysis could be applied to 2H NMR
data of alternative glucuronides such as menthol glucuro-
nide, which can be more easily purified from urine and has
fully resolved glucuronide 2H signals in its original form
(22). Compared to plasma glucose, the analysis of glucuro-
nide 2H enrichment is less informative since the hexose
position 6 hydrogens are removed during the conversion
of UDP-glucose to glucuronide. The absence of position 6
2H-enrichment information means that the contributions
of phosphoenolpyruvate (PEP) and glycerol to gluconeo-
genesis, which relies on quantifying 2H-enrichment in
both positions 5 and 6 (1), cannot be resolved. Gluconeo-
genesis measurement cannot be performed if there are
contraindications to acetaminophen, such as advanced cir-
rhosis, or if the subject is inherently unable to synthesize
significant levels of glucuronide, such as patients with
UDP-glucuronosyl transferase deficiency (23). There is ad-
ditional uncertainty in the glucuronide sampling interval
due to a 30- to 60-min lag time from its hepatic site of
formation to reaching the bladder (24). Hepatic glucuro-
nide and glucose may exhibit different enrichment pat-
terns from certain tracers as a result of metabolic zonation
(25). Glycogen metabolism and glucuronide synthesis are
both located in the pericentral region of the hepatic lobule,
whereas glucose secretion is predominantly in the peripor-
tal region (26,27). To the extent that there is a difference in
the gluconeogenic contribution to G6P synthesis in peri-
portal vs. pericentral hepatocytes, plasma glucose and uri-
nary glucuronide could report different fractional contri-
butions of gluconeogenesis to GP. For a small group of
healthy subjects, plasma glucose and urinary glucuronide
provided equivalent estimates of gluconeogenesis (10), but
this has not been tested in larger subject populations or in
patients with disorders of glucose metabolism.
Our results suggest that the gluconeogenic contribution
to GP had a tendency to be modestly higher in lean nor-
moglycemic KTx patients undergoing CsA-based immuno-
suppressant therapy compared to healthy controls, but this
difference did not reach statistical significance in our
study. Substrate selection for hepatic GP can be modified
by changes in insulin action as well as by the availability
of oxidizable substrates such as FFAs. Hepatic glycogen-
olysis is suppressed by insulin (28) and enhanced by glu-
cagon (28), and is therefore sensitive to alterations in
plasma insulin levels (28). FFAs can stimulate gluconeo-
genesis, possibly via augmentation of hepatic ATP and
NADH production (29,30). They may also increase the rate
of glycogenolysis by impairing its suppression by insulin
(30). While CsA has been reported to reduce pancreatic
insulin secretion (31), possibly by inducing -cell apopto-
sis (32), neither the normo- nor the hyperglycemic CsA
patients of our study had significantly different plasma
insulin levels compared to healthy controls, at least under
basal fasting conditions. Therefore, our data suggest that
the observed alterations in GP sources are not due to
defective insulin secretion during fasting. Moreover, ho-
meostasis model assessment of insulin resistance (HOMA-
IR) indices for the three subject groups were similar, sug-
gesting that insulin sensitivity, as determined by this
method, was not significantly modified in KTx patients.
While plasma FFA levels were not significantly different
between healthy, lean/normoglycemic and obese/hyper-
glycemic KTx patients, there was a tendency for FFA lev-
els to be higher in the KTx patients, with the highest
values found for the obese group.
In summary, for KTx patients undergoing CsA immuno-
suppressant therapy, the gluconeogenic contribution to GP
is significantly increased in the setting of posttransplant
diabetes. This metabolic alteration is most strongly asso-
ciated with adiposity and BMI, but may also be associated
with elevated plasma FFA. There was no association be-
tween the gluconeogenic contribution to GP and either
fasting plasma insulin levels or insulin sensitivity as de-
termined by HOMA-IR. The Bayesian analysis of urinary
glucuronide 2H-enrichment allows an objective evaluation
of hepatic GP sources to be easily integrated with other
simple and practical measurements of human glucose ho-
meostasis.
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